EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves ...

It will not be the most expensive but it will not be the cheapest – a very effective drug at the same list price as Gilenya.” When NICE assessed Gilenya back in 2012, it said the drug costs ...